MXPA04000615A - Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor. - Google Patents

Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.

Info

Publication number
MXPA04000615A
MXPA04000615A MXPA04000615A MXPA04000615A MXPA04000615A MX PA04000615 A MXPA04000615 A MX PA04000615A MX PA04000615 A MXPA04000615 A MX PA04000615A MX PA04000615 A MXPA04000615 A MX PA04000615A MX PA04000615 A MXPA04000615 A MX PA04000615A
Authority
MX
Mexico
Prior art keywords
adrenoceptor
alpha
prevention
treatment
disease mediated
Prior art date
Application number
MXPA04000615A
Other languages
English (en)
Inventor
Joutsamo Topi
Original Assignee
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20011560A external-priority patent/FI116940B/fi
Application filed by Juvantia Pharma Ltd Oy filed Critical Juvantia Pharma Ltd Oy
Publication of MXPA04000615A publication Critical patent/MXPA04000615A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a compuestos de la formula (I) (ver formula) o una sal de los mismos farmaceuticamente aceptables, caracterizado porque R1, R2, R3, R4 y R5 son de manera independiente entre si H, un grupo alquilo o alcoxi recto o ramificado con 1 a 4 atomos de carbono, o un halogeno; X es H, una cadena de alquilo recta o ramificada con 1 a 4 atomos de carbono, fenilo, -OH o =O; Z es H, acetilo, -CH2-Ph-O-CF3 o -CH2-Ph-CF3, Y es una estructura de anillo opcionalmente ligada a la formula (I) con una cadena que tiene uno o dos atomos de carbono. Esta invencion se refiere ademas al uso de dichos compuestos para elaborar una preparacion farmaceutica util para el tratamiento o la prevencion de una enfermedad mediada por el alfa-2B-adrenoceptor en un mamifero.
MXPA04000615A 2001-07-20 2002-07-22 Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor. MXPA04000615A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30644901P 2001-07-20 2001-07-20
FI20011560A FI116940B (fi) 2001-07-20 2001-07-20 Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
PCT/FI2002/000643 WO2003008387A1 (en) 2001-07-20 2002-07-22 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor

Publications (1)

Publication Number Publication Date
MXPA04000615A true MXPA04000615A (es) 2004-04-20

Family

ID=26161203

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000615A MXPA04000615A (es) 2001-07-20 2002-07-22 Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.

Country Status (10)

Country Link
EP (1) EP1417182A1 (es)
JP (1) JP2004535467A (es)
CA (1) CA2454187A1 (es)
HU (1) HUP0401076A2 (es)
IL (1) IL159511A0 (es)
MX (1) MXPA04000615A (es)
NZ (1) NZ530366A (es)
PL (1) PL367040A1 (es)
RU (1) RU2004105035A (es)
WO (1) WO2003008387A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI118265B (fi) * 2004-01-15 2007-09-14 Jurilab Ltd Oy Menetelmä akuutin sydäninfarktin ja sepelvaltimotaudin riskin havaitsemiseksi
PL1861101T3 (pl) 2005-03-23 2013-06-28 Klat Pharma Animal Health Gmbh Zastosowanie amidów sulfadymidyny do leczenia chorób jelitowych u zwierząt
CN111225917A (zh) 2017-10-24 2020-06-02 拜耳股份公司 取代咪唑并吡啶酰胺及其用途
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents
EP1253926A1 (en) * 2000-02-11 2002-11-06 Oy Juvantia Pharma Ltd Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
CA2407587A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited Ppar.gamma. modulators

Also Published As

Publication number Publication date
RU2004105035A (ru) 2005-06-27
IL159511A0 (en) 2004-06-01
WO2003008387A1 (en) 2003-01-30
NZ530366A (en) 2005-02-25
HUP0401076A2 (hu) 2004-09-28
EP1417182A1 (en) 2004-05-12
PL367040A1 (en) 2005-02-21
CA2454187A1 (en) 2003-01-30
JP2004535467A (ja) 2004-11-25

Similar Documents

Publication Publication Date Title
NZ514873A (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
MXPA04000532A (es) Derivados de 8-metoxi-(1,2,4)-triazolo(1,5-a)piridina y su uso como ligandos receptores de adenosina.
MXPA03005464A (es) Agentes antivirales.
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
SE0104334D0 (sv) Therapeutic agents
AP1541A (en) New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
HUP0401638A2 (hu) Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények
DK0409406T3 (da) Arylsubstituerede aminderivater, der er anvendelige ved cancerterapi
MXPA04003935A (es) Derivados de piridina como bloqueadores del subtipo de receptores n-metil-d-aspartato.
ATE308540T1 (de) Antithrombosemittel
MXPA04005077A (es) Derivados de benzotiazol.
MXPA04000615A (es) Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.
IL160082A0 (en) Quinoline derivatives and use thereof as antitumor agents
MXPA04001171A (es) Compuestos policiclicos condensados.
BR0107630A (pt) Composição
ATE238300T1 (de) (3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl)-3-(1 - indol-3-yl)-alkylamine
NO20033049D0 (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1
KR910002818A (ko) 4,5,6,7-사치환된 벤즈옥사졸론
WO2003070703A3 (en) Hydroxylated indirubin derivatives
HUP0400744A2 (hu) Piridoindolon származékok felhasználása rákellenes gyógyszerek előállítására
HUP0303004A2 (hu) Új [(alkil-fenil)-imino]-imidazolidin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk vizeletinkontinencia kezelésére szolgáló gyógyszerkészítmények előállítására